[
  {
    "ts": null,
    "headline": "Agilent Technologies (NYSE:A) Expands Cancer Diagnostic Kit Indications In EU For NSCLC And Melanoma",
    "summary": "Agilent Technologies (NYSE:A) recently achieved EU IVDR approval for two new indications of its PD-L1 IHC 28-8 pharmDx kit, expanding treatment options for early-stage NSCLC and advanced melanoma. While this significant advancement in oncology diagnostics highlights the company's innovative edge, Agilent's stock saw a weekly decline of 3.51%. This price movement occurred against a backdrop of broader market volatility, driven by economic and political uncertainties including the Trump...",
    "url": "https://finnhub.io/api/news?id=8eb390f20ea93385f9568c3de6e8ce70c11b26f109f1f504adefcef94ee9c197",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741714648,
      "headline": "Agilent Technologies (NYSE:A) Expands Cancer Diagnostic Kit Indications In EU For NSCLC And Melanoma",
      "id": 133189156,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "A",
      "source": "Yahoo",
      "summary": "Agilent Technologies (NYSE:A) recently achieved EU IVDR approval for two new indications of its PD-L1 IHC 28-8 pharmDx kit, expanding treatment options for early-stage NSCLC and advanced melanoma. While this significant advancement in oncology diagnostics highlights the company's innovative edge, Agilent's stock saw a weekly decline of 3.51%. This price movement occurred against a backdrop of broader market volatility, driven by economic and political uncertainties including the Trump...",
      "url": "https://finnhub.io/api/news?id=8eb390f20ea93385f9568c3de6e8ce70c11b26f109f1f504adefcef94ee9c197"
    }
  }
]